BioHarvest Sciences (BHST) versus Its Competitors Critical Review

BioHarvest Sciences (NASDAQ:BHST) is one of 1,068 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare BioHarvest Sciences to similar businesses based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, dividends, profitability and risk.

Valuation & Earnings

This table compares BioHarvest Sciences and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioHarvest Sciences	$22.43 million	-$12.56 million	-4.02
BioHarvest Sciences Competitors	$9.96 billion	$135.48 million	-8.31

BioHarvest Sciences’ rivals have higher revenue and earnings than BioHarvest Sciences. BioHarvest Sciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

BioHarvest Sciences has a beta of 2.65, suggesting that its stock price is 165% more volatile than the S&P 500. Comparatively, BioHarvest Sciences’ rivals have a beta of 3.64, suggesting that their average stock price is 264% more volatile than the S&P 500.

Profitability

This table compares BioHarvest Sciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-76.65%	N/A	-85.16%
BioHarvest Sciences Competitors	-3,409.82%	-235.83%	-32.89%

Analyst Ratings

This is a summary of current ratings and price targets for BioHarvest Sciences and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	0	0	2	0	3.00
BioHarvest Sciences Competitors	8194	21885	49779	1316	2.54

BioHarvest Sciences presently has a consensus target price of $13.00, suggesting a potential upside of 158.45%. As a group, “Pharmaceutical preparations” companies have a potential upside of 207.20%. Given BioHarvest Sciences’ rivals higher possible upside, analysts clearly believe BioHarvest Sciences has less favorable growth aspects than its rivals.

Institutional and Insider Ownership

44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.6% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

BioHarvest Sciences rivals beat BioHarvest Sciences on 8 of the 13 factors compared.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.